About us
Evidax helps biotech and pharma build robust evidence packages for market access.
We generate comparative evidence for market access when head-to-head trial data are limited
Either your pivotal evidence comes from a single-arm trial. Or randomised data exists but not against the treatments patients actually receive.
This is too often the case. And it leaves HTA bodies, payers, and clinical teams asking questions the pivotal data cannot answer.
Evidax was built to address exactly this. We use advanced methods and purpose-built workflows to generate new comparative evidence from published and real-world data that already exists.
The end result is a robust evidence package, combining your pivotal trial data with external evidence, that holds up to HTA and payer scrutiny.
Our guarantee
We agree an outcome and a price from the outset. We then guarantee to work with you until that agreed outcome is delivered, with no additional charges.
Meet the team
Dr Sam Orange
Founder & Chief Scientific Officer
Sam has spent the last 15 years leading translational and clinical research programmes across biotech and healthcare. He has generated evidence to inform clinical practice and clinical guidelines, and he has taken his own asset from conception to patent pending. He is an expert in evidence synthesis, having conducted over 60 systematic reviews for development purposes and published over 12 in peer-reviewed scientific journals.
Professor Ian Hickson
Senior Scientific Adviser: Drug discovery
Ian is Professor of Cancer Drug Discovery at Newcastle University, UK. He has 30 years of experience in oncology research and 25 years in drug discovery, including senior roles at KuDOS Pharmaceuticals and Janssen, where he led discovery, translation and early clinical development programmes. His work has contributed to several molecules entering clinical testing, and his expertise spans target validation, translational strategy and early drug development.
Dr Tom Maden-Wilkinson
Senior Scientific Advisor: Biotech strategy
Tom is an Associate Professor at Sheffield Hallam University and Scientific Director at Emles Bioventures, UK. He is an internationally recognised expert in muscle physiology and has led major translational and clinical research programmes across academia and biotech, with particular expertise in assessing neuromuscular function. For the past decade, he has provided strategic scientific advice to biotech and pharmaceutical companies.
Professor James Wason
Senior Scientific Advisor: Biostatistics
James Wason is a Professor of Biostatistics at Newcastle University. He is an internationally leading expert in methods for making clinical trial designs and analyses more efficient. His research spans multiple areas of clinical trials methodology, including adaptive clinical trial design, analysis of composite endpoints, and use of external information to augment trials.
Ben Porter
Senior Scientific Advisor: RWE and evidence synthesis
Ben is a health innovation specialist with experience spanning rare disease, patient registries, horizon scanning and the assessment of emerging health technologies. He has worked across NHS, academic, health innovation network and life science settings, leveraging real-world evidence to support clinical development and regulatory requirements, innovation assessment and engagement with NICE, alongside helping innovators and industry understand routes towards evaluation and adoption.